Abstract: Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.

Abstract: The invention describes a pharmaceutical association of active ingredients comprising: curcumin, quercetin, chondroitin sulfate and hyaluronic acid, used for the prevention or treatment of bladder, pelvic and urogenital apparatus pathologies.

Abstract: The present invention relates to a downstream industrial method of purifying chondroitin sulphate obtained from animal cartilage, which produces a product fully compliant with the specifications required for the use of said compound in the pharmaceutical field.

Abstract: Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.

Abstract: The invention relates to a new composite based on hydroxypropyl-?-cyclodextrin, sucralose, a pharmaceutically active ingredient (API) complexed in said hydroxypropyl-?-cyclodextrin, and optionally an aqueous vehicle. The composite is obtainable by a complexation process of the API in hydroxypropyl-?-cyclodextrin, carried out in the presence of sucralose. The composite ensures a surprisingly high API bioavailability through buccal route of absorption, due to a high absorption rate through the oral membrane. The composite is therefore suitable for the preparation of oromucosal pharmaceutical compositions, e.g. buccal or sublingual tablets, orodispersible film, etc., having high bioavailability.

Abstract: The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.

Abstract: Disclosed are soft gelatin capsules comprising a gelatin shell, a plasticiser, water, and optionally a calcium salt and a filling containing a dispersed or solubilised medicament comprising gelatin with gelling power, hydrolysed gelatin, glycerol, water, pectin and gellan gum. The formulations according to the invention allow gradual release of the active ingredient, regardless of pH.

Abstract: Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.

Abstract: Disclosed are ophthalmic formulations which use complexes called L/H-HA, obtainable by subjecting at least two fractions of hyaluronic acids and/or other glycosaminoglycans with different molecular weights to an appropriate heat cycle.

Abstract: Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.

Abstract: A composition for topical application characterized in that it includes, in a hydrogel base, vanillyl butyl ether and menthol. The composition described herein produces an ordered development of cold and warm sensations, obtaining effects that are particularly useful in the treatment of painful disorders of neurological and/or muscular origin. The composition has further moisturizing and soothing effects that concur to an effect that is also curative, i.e., not simply symptomatic, of rheumatic and muscular pain, trauma and bruises. The composition is compatible with each administration form, being preferably and advantageously formulated as a plaster.

Abstract: A composition for topical application characterized in that it includes, in a hydrogel base, vanillyl butyl ether and menthol. The composition described herein produces an ordered development of cold and warm sensations, obtaining effects that are particularly useful in the treatment of painful disorders of neurological and/or muscular origin. The composition has further moisturizing and soothing effects that concur to an effect that is also curative, i.e., not simply symptomatic, of rheumatic and muscular pain, trauma and bruises. The composition is compatible with each administration form, being preferably and advantageously formulated as a plaster.

Abstract: Disclosed is a process for the production of chondroitin sulphate, wherein N-acetyl-galactosamine residues sulphated at the 4- or 6-positions are present on the same polysaccharide chain.

Abstract: The invention discloses stable formulations of acetylsalicylic acid or salts thereof, omega-3 fatty acids and amylose in soft gelatin capsules.

Abstract: The invention describes a pharmaceutical association of active ingredients comprising: curcumin, quercetin, chondroitin sulfate and hyaluronic acid, used for the prevention or treatment of bladder, pelvic and urogenital apparatus pathologies.

Abstract: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.

Abstract: Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.

Abstract: A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.

Abstract: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.

Abstract: The invention relates to the use of an additive to stabilise hyaluronic acid formulated in an aqueous composition against the degrading effect of heat or of enzymes such as hyaluronidase, characterised in that said additive comprises one or more polysaccharides having a molecular weight equal to or greater than 20,000 daltons and solubility in water at least equal to or greater than 1 g/l, the total concentration of said polysaccharide(s) and hyaluronic acid in the composition giving it a viscosity of at least 500 cP, which is particularly suitable for intra-articular, intradermal or intraocular administration to humans or animals.